Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

Rheumatology

Systemic Lupus Erythematosus (SLE) - Part II: New Treatments for Mild SLE

This month, Elena Peeva, M.D., M.Sc., Gisele Zandman-Goddard, M.D., and Peter Barland, M.D. discuss
CME credit is no longer available for this conference.

Course Authors

Elena Peeva, M.D., M.Sc., Gisele Zandman-Goddard, M.D., and Peter Barland, M.D.

Dr. Peeva is Instructor of Medicine at the Albert Einstein College of Medicine and Attending Physician at Montefiore Medical Center, New York; Dr. Zandman-Goddard is Instructor of Medicine and Attending Physician at Sheba Medical Center, Israel.Drs. Peeva, Zandman-Goddard and Barland report no commercial conflicts of interest.

Release Date: 03/01/2001

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Describe the mechanism of action and major side effects of the new cytotoxic agents used in treatment of SLE: MMF, fludarabine and cladribine

  • Discuss induction of B cell tolerance by LJP 394

  • Describe the stem cell restoration treatment and the mechanism of action and effects of intravenous immunoglobulin

  • Describe the mechanism of action of targeted molecular therapies.

 

TERMS AND CONDITIONS

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms.

Courses You Might Like

Fibromyalgia: Current State of the Art

women. Despite its high burden, the pathophysiology of FM remains poorly understood, leading to challenges in diagnosis and treatment. Over the past decade, research has advanced our understanding of FM. The disorder is now linked to central nervous system (CNS) dysfunction, altered neurotransmitter activity and immune dysregulation. …
Authors: Danilo De Gregorio, PharmD, Ph.D.
View Course
More

Treatment of Idiopathic Inflammatory Myopathy

With few FDA-approved medications available, the treatment of myositis is challenging.
Authors: Siamak Moghadam-Kia, M.D., Rohit Aggarwal, M.D. and Chester V. Oddis, M.D.
View Course
More

Idiopathic Inflammatory Myopathies: A 2016 Update

Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune diseases, primarily affecting the skeletal muscles, which cause predominant proximal muscle weakness.
Authors: Julie J. Paik, M.D.. M.H.S. and Lisa Christopher-Stine, M.D., M.P.H.
View Course
More

The Current Treatment of Lupus Nephritis

Despite therapeutic advances, lupus nephritis continues to lead to significant morbidity and mortality with 10-15% of patients progressing to end-stage renal disease requiring renal replacement therapy.
Authors: Saakshi Khattri, M.D., and Peter Barland, M.D
View Course
More

Palindromic Rheumatism

An episodic recurring arthritis with unknown etiopathogenesis.
Authors: Sahitya Mallipeddi, M.D., Raghu Maddela, M.D., and Peter Barland, M.D.
View Course
More

Immunoglobulin G4-related Sclerosing Syndrome

This month, Peguy Saad, M.D., and Peter Barland, M.D., discuss

cells. It is also known for its dramatic response to steroids. The recent identification of IgG4 in the affected tissues of many chronic inflammatory syndromes has led to the recognition of a new clinicopathological entity — IgG4 RSS. Prior to the discovery of IgG4 RSS as a multiorgan disorder, many…
Authors: Peguy Saad, M.D., and Peter Barland, M.D.
View Course
More